Daily Stock List
Finavera Wind Energy, Inc. (FVR.V)
Investor Ideas and Green Chip Stocks reported previously on Finavera Wind Energy, Inc. (FVR.V), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.
Founded in Dublin, Ireland in 2003, Finavera Wind Energy, Inc. focuses on developing, constructing and operating wind farms in North America and Ireland. Listed on the TSX Venture Exchange, the Company formerly went by the name Finavera Renewables, Inc. They changed their name to Finavera Wind Energy, Inc. in February 2011. With four energy projects in British Columbia (BC), Finavera will be generating 301 megawatts of clean energy by program completion in 2015. The Company has their corporate headquarters in Vancouver, British Columbia.
Finavera's mission is to create and operate a diversified portfolio of wind projects while protecting and enhancing the physical and social environment. All four of Finavera's BC wind projects (totaling 300 MW) have been awarded 25-year AAA-rated Electricity Purchase Agreements with BC Hydro. This will provide the Company a stable revenue stream when in operation. One of their projects has received full environmental approval and permitting for construction, expected to start in 2013.
Finavera is building on a proven record of accomplishment of wind development in Ireland's Cloosh Valley. They signed an agreement with Scottish and Southern Energy for the co-development of a 105 MW project on Ireland's West coast. A strong pipeline of future projects is also undergoing development.
Last week, Finavera Wind Energy announced that after a thorough review of several corporate transaction options and a number of proposals from interested parties, the Company's Special Committee of the Board recommended and approved the signing of an agreement with Pattern Renewable Holdings Canada ULC, a subsidiary of Pattern Energy Group, LP. This is for the sale of the Company's 300-megawatt (MW) British Columbia wind project portfolio for approximately $40 million.
Finavera Wind Energy CEO Jason Bak said, "This transaction is a testament to the quality of our portfolio and is an excellent example of the monetization of value created through our development skill set. The transaction indicates a significant difference between our market capitalization and our inherent value as in addition to the $40 million in proceeds payable on the projects proceeding to construction, Finavera maintains a 10 percent interest in the 105 MW Cloosh Valley Wind Project and is expecting an additional $9.3 million payment from the project in 2013. With the cash proceeds that will be received by Finavera from these transactions, we will be well-positioned to continue to pursue further high growth opportunities in renewable power development."
Finavera Wind Energy, Inc. (FVR.V), closed Thursday's trading session at $0.225, up 15.38%, on 368,000 volume. The stock's 52-week low/high is $0.13/$0.50.
Migao Corp. (MGO.TO)
Today we are highlighting Migao Corp. (MGO.TO), here at the QualityStocks Daily Newsletter.
Migao Corp. produces specialty potash-based fertilizers for the high-value agricultural Chinese market. Since 2003, the Company has established four operating locations in China, with new facilities undergoing construction in Shanghai, Tianjin and Zunyi. Currently, Migao is producing their two core products – potassium nitrate and potassium sulphate, at the four operating locations. Migao has offices in Beijing and in Toronto, Ontario. The Company's shares trade on the Toronto Stock Exchange.
Migao's patented technology allows them to offer a consistent and reliable supply of high quality fertilizers. These fertilizers are ideal for high-value crops such as fruits and vegetables, tobacco, and cotton. The potassium nitrate and potassium sulphate products comprise 85 percent of the Company's revenue. The balance of revenue comes from the sale of fertilizer manufacturing by-products – ammonium chloride, a nitrogen-bearing fertilizer, and hydrochloric acid, a chemical with major industrial demand.
Migao sells their products to tobacco, fruit, and vegetable growers primarily in the People's Republic of China. The Company's Sichuan facility is ISO 14001 certified, which is an international environmental management standard.
In November, Migao announced that Ms. Helen Lu, CA, CPA, CFA was appointed Chief Financial Officer (CFO). Ms. Lu has years of experience in Canada and China serving public and private companies. Ms. Lu, as CFO of Yalian Steel, brings experience for the challenges of a Canadian listed company with operations in China. Previously, she held the position of Audit Manager at Ernst & Young in Vancouver and Senior Auditor at Ernst & Young's Shanghai office. Ms. Lu was Assistant Vice President at Citigroup in Shanghai; she oversaw the internal control practice among other responsibilities. Ms. Lu is fluent in English, Mandarin, and Cantonese.
The anticipation is that the Company's Sichuan Migao and Liaoning Migao will operate at full capacity for the balance of fiscal 2013. The Company's joint venture potassium nitrate facility is anticipated to be at full capacity for the balance of fiscal 2013, as well as the specialty compound facility at Zunyi Migao. The anticipation is that Guangdong Migao will reach approximately 60-70 percent of capacity, Changchun Migao at 50-60 percent, and Shanghai Migao at 50-60 percent of capacity by the end of fiscal 2013.
Migao Corp. (MGO.TO), closed Thursday's trading session at $1.38, down 0.72%, on 21,300 volume. The stock's 52-week low/high is $1.25/$4.28.
Poly Shield Technologies, Inc. (SHPR)
We are reporting on Poly Shield Technologies, Inc. (SHPR), here at the QualityStocks Daily Newsletter.
Headquartered in Boca Raton, Florida, Poly Shield Technologies, Inc. is the marketing company for patented Fluoropolymer coatings, Shield Products, which are manufactured by their exclusive production facility. The Company has an exclusive contract to distribute commercial and industrial protective coating products produced by Shield Products, Inc., with the exception of existing customers of Shield Products at the time the contract was signed. In addition, Poly Shield offers a state-of-the-art line of antimicrobial coatings.
The commercial and industrial protective coating products they distribute have specific application in the industries of space technology, oil exploration and production, commercial ship maintenance, amusement parks, construction and building preservation. On March 12, 2012, Poly Shield entered into an agreement to purchase the rights to market the products of Teak Shield Corp. (Teak Shield). Teak Shield has a proprietary process for the production of flouropolymer coatings used to protect surfaces from corrosion, oxidation and ultraviolet degradation.
Further to Poly Shield's License Agreement with Teak Shield, the Company has a royalty agreement with WebTech Wireless, Inc., under which they have a royalty right to 6 percent of gross qualified sales.
During the next year, Poly Shield Technologies plans to refine their business and marketing plan for the Shield Products and expand their presence in the flouropolymer coating market.
Poly Shield coatings have the industry's longest lasting protection, extending the life and the appearance of surfaces for up to 20 to 30 years. The Company's coatings can be applied on virtually any surface. Poly Shield's products include SuperShield, SuperiorShield, and MicroShield. SuperShield is a unique patented fluoropolymer coating that is formulated to work with a variety of residential, commercial, industrial and marine applications. SuperiorShield is their line of unique protective and energy saving roof coatings. MicroShield is their unique line of anti-microbial coatings.
Earlier this month, Poly Shield Technologies announced that on December 6, 2012, they entered into an employment agreement dated December 1, 2012, with Mr. Rasmus Norling. The effectiveness of the Employment Agreement is contingent upon Mr. Norling arranging or procuring on behalf of the Company minimum rights (the Minimum Technology Rights) to certain emission abatement technologies, with the effective date of the Employment Agreement being the later of December 15, 2012 or the date the Minimum Technology Rights are delivered to the Company. Under the terms of the Employment Agreement, upon the Effective Date (and conditional upon the Minimum Technology Rights), Mr. Norling will be appointed as the Company's Chief Executive Officer.
Poly Shield Technologies, Inc. (SHPR), closed Thursday's trading session at $0.45, even for the day, on 7,251 volume with 5 trades. The average volume for the last 60 days is 6,788 and the stock's 52-week low/high is $0.075/$1.01.
Worldwide Food Services, Inc. (WFSV)
StockMister reported recently on Worldwide Food Services, Inc. (WFSV), Wallstreetbuzz did earlier, and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Worldwide Food Services, Inc. operates a marketing and distribution system for food and beverage products. In addition, the Company manages and monitors private sector, as well as veteran and blind government programs. Worldwide Food Services' shares trade on the OTC Markets: OTC Pink Current Information. The Company has their corporate headquarters in Bordentown, New Jersey.
Worldwide Food Services focuses on using government resources to educate, train, and support veterans and visually handicapped citizens and groups. The Company's programs provide an income stream from food and beverage programs in post offices, court houses, penitentiaries, and VA hospital facilities, as well as from subsidized rent and equipment for vending and cafeteria businesses.
In July 2012, Worldwide Food Services announced that they completed their acquisition of Smart Diet Rx, Inc. This new division of the Company will handle the Condition Specific/Disease Specific meals aimed at reducing hospital re-admission rates because of poor follow-through on given nutritional standard requirements of heart, cancer, diabetes, obesity, and high blood pressure patients and individuals. Recently, the Company announced that they completed their acquisition of Wellness Juices, Inc. Wellness Juices is in negotiations with a major production and bottling company to distribute their products.
Last month, Worldwide Food Services announced that after a thorough review of the Company's economic options, the Board of Directors decided to move the Company offices to Mexico City, Mexico. Logistics of the Commodities Division, coupled with the anticipated tax increases and the impact of "ObamaCare" have led to this corporate decision by the Board. Worldwide Food Services will maintain a mailing address in Bordentown, New Jersey.
In addition, last month, Worldwide Food Services announced that they signed a Memorandum of Understanding (MOU) with a manufacturing company in Mexico. The MOU is to produce, bottle, and distribute Wellness Juices. This "Joint Venture" could lead to an acquisition.
Worldwide Food Services, Inc. (WFSV), closed Thursday's trading session at $0.055, even for the day, on 50,928 volume with 6 trades. The average volume for the last 60 days is 45,654 and the stock's 52-week low/high is $0.04/$0.65.
Face Up Entertainment Group, Inc. (FUEG)
StockMister, StockBomb.com, StockLockandLoad, StockRockandRoll, The Stock Brainiac, Stock Edge, Your Stock Alert, and PennyStockLocks.com reported recently on Face Up Entertainment Group, Inc. (FUEG), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Face Up Entertainment Group, Inc. is the Internet’s first Reality Gaming Social Network. The Company operates faceupgaming.com, a non-wagering Internet gaming Website that provides users with streaming video, audio, and messaging capabilities. The Company formerly went by the name Game Face Gaming, Inc. They changed their corporate name to Face Up Entertainment Group, Inc. in April of this year. Face Up Entertainment Group has their headquarters in Valley Stream, New York.
Face Up is a gaming company whose commitment is to responsible game-play and their platform is not a gambling site. The Company's goal is to maintain the thrill of online games while keeping it safe for everyone. They will be collaborating with agencies, groups and associations to help promote safe and responsible game play, and to provide a channel to assistance for those with gambling addictions.
Their Poker game is played live, interactively, utilizing video and chat and allows for poker play in its true form and as intended, to be played online for the first time. As pertains to future products, Face Up's proprietary platform will be used to create an extensive worldwide gaming network. It will consist of games from every region of the globe, supporting native languages and cross language functionality.
Face Up Group will also be launching their in-house developed games. They will quickly expand the network to include global staples in gaming such as Backgammon, Chess and Checkers.
This month, Face Up Entertainment Group announced that their 2013 Aruba Poker Open will take place at The Radisson Resort & Casino in Aruba in early December 2013. The Company is planning to take as many as 100 players to Aruba next year, a substantial increase over this year. Given the response to the recently completed 2012 tournament, Face Up is in negotiations with The Radisson Resort & Casino - Aruba to rapidly expand this tournament to multiple locations and also for over branding the Company's name and logo onto a portion of their poker tables.
Face Up Entertainment Group, Inc. (FUEG), closed Thursday's trading session at $0.22, even for the day, on 3,450 volume with 3 trades. The average volume for the last 60 days is 39,993 and the stock's 52-week low/high is $0.025/$0.42.
RVPlus, Inc. (RVPL)
Alternative Energy and OTCPicks reported earlier on RVPlus, Inc. (RVPL), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
RVPlus, Inc., via their subsidiaries, is a global interface for universal clean technologies that are sustainable, energy efficient, and reduce carbon-emissions. RVPlus is the holding company of ECCO2 Tech. The ECCO2 (acronym for Environmental Control of Carbon Dioxide) concept and business was founded in 2007 by Cary Lee Peterson. It was later acquired by their parent company, RVPlus in May 2012. RVPlus lists on the OTC Bulletin Board.
ECCO2 Tech solutions consist of a suite of clean-tech solutions, which are late stage technology grids that have a proven record of accomplishment in the marketplace. Diverse commercial and government organizations around the world are currently using these solutions. ECCO2 Tech is a middle market provider to clean technology supply chains that are eligible for local, federal, and foreign tax credits, rebates, grants, and financial aid programs. ECCO2 Tech collaborates with sister company, ECCO2 Corp., a not-for-profit company.
Some of ECCO2 Tech's leading technology solutions include Stainless Steel Oil, Fuel and Hydraulic filters for all engines and generators requiring filtration. This includes all transport, industrial boilers and machinery. Their solutions also include Green Housing Development - rehabilitating and providing more energy efficient, livable, and sustainable communities adhering to Energy Star best practices and certified products. In addition, their solutions also include Metal Conditioners - Power Curve XP-AC is an innovative advancement in extreme lubrication technology for air conditioning and refrigeration systems.
RVPlus recently announced that ECCO2 entered into a material agreement for $90 million to supply green technologies chains that enable the environment, agriculture, climate change and economy in the Republic of Haiti over the next ten years. The Company also has a quarterly report filed in October 2012 showing a material agreement with foreign federal government that will generate $250 million in sales over the next year alone.
Last week, RVPlus filed their 10Q, which showed, among other things, $8.66 million in accounts receivable as of October 31, 2012. The projection is that RVPlus will see $275 million in sales over the next year due to purchase agreements with foreign government parties.
RVPlus, Inc. (RVPL), closed Thursday's trading session at $0.10, up 100.00%, on 327,550 volume with 42 trades. The average volume for the last 60 days is 11,010 and the stock's 52-week low/high is $0.04/$0.59.
TransBioTec, Inc. (IMLE)
NanoCap Gems and OTCPicks reported previously on TransBioTec, Inc. (IMLE), and we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Based in Seal Beach, California, TransBioTec has developed and patented a non-invasive alcohol sensing system 'SOBR'. It works as a type of ignition interlock that functions through transdermal, biometric feedback. The technology works by sensing ethanol alcohol through sweat secretion from the hands. The alcohol sensing system offers a unique solution to the national drunk driving epidemic.
Upon the development and testing of SOBR, TransBioTec plans to market the device to four primary business segments. One is as an aftermarket-installed device to companies and institutions that employ or contract with vehicle drivers (e.g. trucking companies, limousine companies, and taxicab companies) where the system will be marketed as a preventative drunk driving detection system, with a possible ignition-locking device.
The second is the original equipment manufacturing (OEM) market, where the device would be installed in new vehicles during the original building of a vehicle. The third is companies and institutions that have an interest in monitoring their employees or contractors' alcohol level due to their job responsibilities. The fourth is companies that would want to provide knowledge to their customers of their current alcohol level, such as lounge and bar owners, or customers attending a golfing event.
SOBR technology consists of two parts: the blood alcohol detection technology and the ignition interlock device connected by way of a microprocessor. SOBR is the first product to market that is entirely neither intrusive nor invasive keeping the vehicles crucial aesthetic appeal to the general population while having the ability to be fitted to any vehicle.
As either a retrofitted or a factory built-in device, the steering wheel of any vehicle becomes the sensor platform. When a driver grasps the steering wheel, the ultra-efficient sensor detects the vapors and determines the precise contents of those vapors, in terms of alcohol level. This information is instantly translated into an engine "start" or "no-start" state.
An unsafe measurement will deny the driver the ability to start the engine of the vehicle. If the driver becomes intoxicated while driving, the car horn and the emergency flashers will go off. If the system is tampered with while parked, the car will not start. If tampered with while driving, the alarms will activate.
TransBioTec, Inc. (IMLE), closed Thursday's trading session at $0.096, up 57.38%, on 60,100 volume with 8 trades. The average volume for the last 60 days is 11,512 and the stock's 52-week low/high is $0.06/$0.92.
Buccaneer Energy Ltd. (BCGYF)
Momentum Traders reported previously on Greenbackers reported earlier on Buccaneer Energy Ltd. (BCGYF), and we report on the Company today, here at the QualityStocks Daily Newsletter.
Headquartered in Sydney, Australia, Buccaneer Energy Ltd. is an upstream oil and gas company. The Company specializes in the development and expansion of behind-pipe proved and probable reserves and low-risk exploration plays with growth potential. Their geographic focus is on onshore and shallow waters of the Cook Inlet of Alaska and the Gulf of Mexico, and onshore Gulf Coast assets that have been left behind or overlooked by other players. Buccaneer Energy operates in the U.S. via their wholly owned subsidiaries, Buccaneer Resources and Buccaneer Alaska, with offices in Houston, Texas and Kenai, Alaska.
Buccaneer Energy's growth strategy focuses on the progressive expansion of oil and gas production and reserves by acquiring significant working interests in low-cost, low-risk development properties that possess a significant undeveloped upside. The Company looks for acreage that they can acquire at a low entry price in high quality and prospective areas. All of the Company's projects have multiple pay zones and high cash flow potential.
Buccaneer accumulated several offshore opportunities in 2008 in the shallow Gulf of Mexico stretching between Texas and Louisiana. This increased their reserves by more than 180 percent in a matter of months. Simultaneously, they also purchased acreage in the Eagle Ford Shale under the Austin Chalk in Lee County, Texas. This is one of the oldest producing regions in the United States. The properties are strategically positioned with existing infrastructure. The Company identified and completed the purchase of the assets of Stellar Oil & Gas, LLC in early 2010. With this acquisition, they became the sixth largest leaseholder in the Inlet.
Buccaneer Energy is focusing on developing their 100 percent owned oil & gas assets in Alaska. Their flagship projects are the series of onshore and offshore developmental and exploration prospects in the Cook Inlet. Buccaneer Energy's cash flow strategy includes developing the 100 percent owned Kenai Loop onshore gas project with independently assessed 4.8 MMBOE1 in 2P Reserves; operating an Offshore Jack Up rig for use by third parties in the Cook Inlet; and developing their offshore Cook Inlet projects that have independently assessed 73.3 MMBOE in 2P Reserves/P50 Resources using the acquired Jack Up rig. The Company has a 50/50 joint venture with Singaporean based Ezion, a leader in the development, ownership and chartering of strategic offshore assets, and the Alaskan Industrial Development and Export Authority (AIDEA).
Buccaneer Energy Ltd. (BCGYF), closed Thursday's trading session at $0.055, up 3.77%, on 123,000 volume with 8 trades. The average volume for the last 60 days is 106,987 and the stock's 52-week low/high is $0.04/$0.10.
TNI BioTech, Inc. (TNIB)
The QualityStocks Daily Newsletter would like to spotlight TNI BioTech, Inc. (TNIB). Today, TNI BioTech, Inc. closed trading at $8.10, up 2.02%, on 18,578 volume with 55 trades. The stock’s average daily volume over the past 60 days is 37,185, and its 52-week low/high is $0.72/$10.01.
TNI BioTech, Inc. reported initiation of coverage today by Umbrella Research, which highlighted the company's leading immunotherapy work in cancer, where TNIB has key technology footholds emphasizing activation/mobilization of the body's own immune system. The broad range of infectious disease (HIV for instance), chronic inflammatory disease, and autoimmune disorders within striking distance of the company's technology pipeline is impressive and the near-term commercialization potential in cancer, as well as HIV/AIDS, coupled with Phase III low dose naltrexone (LDN) work slated for 2014 in Crohn’s disease, has Umbrella pegging TNIB at a $26 price target with a "buy" rating.
TNI BioTech, Inc. (TNIB) is focused on utilizing patented immunotherapy to activate and mobilize the body's immune system to combat fatal diseases. The company's products and technologies improve the treatment and diagnosis of cancer, infections such as HIV/AIDS, and autoimmune diseases. Future initiatives include treatment for multiple sclerosis, herpes viral infections, and other conditions that result in altered-immune response.
The company's product portfolio currently includes IRT-101, an active immunotherapy that works by activating a patient's immune system against infectious diseases and tumor cells; IRT-102, an adaptive immunotherapy that works by isolating and enriching a patient's own immune cells; and IRT-103, an active immunotherapy that works by activating a patient's immune system against HIV/AIDS and tumor cells.
Leveraging the advantages of today's cutting-edge treatment options, the company aims to meet the growing demand for quality healthcare with safer, more effective radiation therapy; new-targeted drug therapies; and minimally invasive surgical alternatives around the world. TNI BioTech most recently signed a letter of intent to open clinics in Africa that will provide advanced treatment for cancer, HIV/AIDS, and autoimmune diseases.
The company plans to continue clinical trials in China during 2012 and 2013, and anticipates starting trials in the United States by early 2013.The company is also in negotiations to acquire a number of other immunotherapy products, patents, and therapies. Led by a management team with decades of experience and solid business plan, TNI BioTech is poised to improve healthcare with active and adaptive forms of improved immunotherapies. Disclaimer
TNI BioTech, Inc. Company Blog
TNI BioTech, Inc. News:
Umbrella Research Initiates Coverage on TNI BioTech
TNI BioTech, Inc. Signs Exclusive Distributor Agreement for Federal Republic of Nigeria with G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC
TNI BioTech Inc., and Hubei Qianjiang Pharmaceuticals Co., Ltd., Announce Venture Partnership for the Development of New Drug for Cancer Therapies
Viscount Systems, Inc. (VSYS)
The QualityStocks Daily Newsletter would like to spotlight Viscount Systems, Inc. (VSYS). Today, Viscount Systems, Inc. closed trading at $0.065, up 8.33%, on 374,999 volume with 12 trades. The stock’s average daily volume over the past 60 days is 52,502, and its 52-week low/high is $0.0069/$0.07.
Viscount Systems, Inc. (VSYS) designs, manufactures, and services access control and security products such as door access control systems and emergency communications systems. The company's products have been installed in approximately 35,000 sites in over 30 countries, including prisons, schools, hospitals, and corporate offices.
Designing security systems since 1969, the company has developed strategic working relationships with leading equipment vendors to support its continued profitability and growth. Viscount has been consistently profitable for nearly 15 years and currently generates annual revenues of approximately $5 million.
Five hundred dealers help distribute Viscount's existing products throughout North America. This distribution network is not static as the company constantly pursues additional sales channels. Products are advertised in various print publications and regularly displayed at tradeshows as well. Direct marketing via training seminars also helps drive sales.
Viscount's management team has more than 60 years of combined experience in the development and production of electronic door control and telecommunication systems. Under this leadership, the SIA Convergence Solution of the Year accolade and Platinum Award for Emergency Response and Gold Award for Access Control at the Government Security Awards (GOVSEC) for 2011 have been presented to the company. Disclaimer
Viscount Systems, Inc. Company Blog
Viscount Systems, Inc. News:
Viscount Systems Appoints Dennis Raefield as Chief Operating Officer
Viscount Announces Completion of $500,000 Private Placement
Viscount Systems Wins Contract with Phoenix Sky Harbor Sky Train
VIASPACE, Inc. (VSPC)
The QualityStocks Daily Newsletter would like to spotlight VIASPACE, Inc. (VSPC). Today, VIASPACE, Inc. closed trading at $0.012, up 9.09%, on 370,902 volume with 4 trades. The stock’s average daily volume over the past 60 days is 1,543,968, and its 52-week low/high is $0.0013/$0.015.
VIASPACE, Inc. (VSPC) is focused on growing renewable Giant King™ Grass as a low-carbon fuel for clean electricity generation and environmentally friendly energy pellets, as well as a feedstock for bio-methane production, green cellulosic biofuels, biochemical, and biomaterials. A high-yield, low-cost feedstock, Giant King Grass meets the cost targets of green energy applications while maintaining a carbon neutral profile.
The highest yielding biomass crop in the world, Giant King Grass can grow in a variety of soil conditions and does not compete with food crops. Once Giant King Grass is established, it can be harvested at 3-5 feet tall every 45 to 60 days or at 14 feet tall twice a year. This incredibly high rate of growth provides a continual supply of biomass year-round, enabling strategically located power plants to operate 24 hours a day regardless of the current season.
VIASPACE provides Giant King™ Grass seedlings and technical expertise to qualified projects. The company also plans to serve as a project developer or co-developer for power plant or pellet mill projects, together with local partners that have land and require electricity, heat, pellets, biogas, or biofuels. VIASPACE and its partners are capable of delivering an integrated Giant King Grass plantation and biomass power plant project in just 24 months.
The excellent energy characteristics of Giant King Grass and its ability to be harvested multiple times each year enable and energy output yield that is much higher than other crops . This superior feedstock offers material productivity benefits at remarkable costs for energy production, biofuels, and biomaterials. Giant King Grass is currently being grown in the United States, Virgin Islands, China, and other areas. Disclaimer
VIASPACE, Inc. Company Blog
VIASPACE, Inc. News:
St. Croix Giant King Grass-Fueled Electric Power Plant Design Approved by Public Services Commission
VIASPACE Chairman Interviews With WallStreetReporter and Provides Commentary
VIASPACE Giant King™ Grass Featured in Front-Page Story in St. Croix Newspaper
Cardium Therapeutics, Inc. (CXM)
The QualityStocks Daily Newsletter would like to spotlight Cardium Therapeutics, Inc. (CXM). Today, Cardium Therapeutics, Inc. closed trading at $0.1942, up 2.21%, on 124,554 volume with 86 trades. The stock’s average daily volume over the past 60 days is 199,116, and its 52-week low/high is $0.17/$0.42.
Cardium Therapeutics, Inc. (CXM) is a health sciences and regenerative medicine company focused on acquiring and strategically developing new and innovative products and businesses to address significant unmet medical needs. Comprised of large-market opportunities with definable pathways to commercialization, partnering, and other economic monetizations, Cardium's current portfolio includes the Tissue Repair Company, Cardium Biologics, and the company's in-house MedPodium Health Sciences healthy lifestyle product platform.
The company's lead commercial product Excellagen® topical gel for wound care management recently received FDA clearance for marketing and sale in the United States. In addition to plans to advance the product's commercialization in the U.S. and internationally via strategic partnerships, the company plans to develop new product extensions for additional wound healing applications and is working towards securing approval for marketing and sale in South Korea and through the CE Mark application process in the European Union.
Generx®, Cardium's lead clinical development product candidate, is a DNA-based angiogenic biologic designed to treat patients with myocardial ischemia due to coronary artery disease. Cardium recently initiated its Generx Phase 3 / registration study in Russia. Consistent with its capital-efficient business model, Cardium is also actively evaluating new technologies and business opportunities. The company utilizes its team's skills in late-stage product development to bridge the critical gap between promising new technologies and product opportunities that are ready for commercialization.
Cardium is dedicated to building on its core products and product candidates to continually create new opportunities for greater success. Leveraging the advantages of its capital-efficient, asset-based business strategy, the company provides a diversified and more balanced portfolio of risk/return opportunities with the chief objective of providing long-term shareholder value. Disclaimer
Cardium Therapeutics, Inc. Company Blog
Cardium Therapeutics, Inc. News:
Cardium Announces Patent Award For Rights To Gene Therapy for Coronary Heart Disease, Resolves Long-standing IP Competition
Cardium Presents Third Quarter 2012 Financial Results and Reports on Recent Developments
Cardium Announces Excellagen Poster Presentatons At Desert Foot 9th Annual High Risk Diabetic Foot Conference
Earlier today, TNI BioTech, a biotech company focused on utilizing patented immunotherapy to activate and mobilize the body’s immune system to combat fatal diseases, announced that Umbrella Research is now covering the company with a “buy” rating and $26 price target.
The entire 33-page report has been posted on the company’s Web site at http://www.tnibiotech.com/investor-relations/reports
The following is an excerpt of the report: “It is our opinion that TNI presents investors with significant upside from current prices based on a two-fold growth strategy including: the near term commercialization of its existing immunotherapies targeting cancer and HIV/AIDS; coupled with the potential contribution from the phase 3 study of low dose naltrexone (LDN) for use in Crohn’s disease, scheduled to begin in 2014. As the company enters 2013 it should be in a position where ramping revenue run rates not only allow it to be self-funding in regard to clinical development costs, but also for this to translate quickly into an earnings driven growth story for investors with significant potential upside from approvals.”
For more information on the company and its immunotherapies, visit www.TNIBiotech.com
VIASPACE recently announced that the St. Croix Public Services Commission (PSC) earlier this week voted to approve Tibbar Energy’s facility design for a 6MW anaerobic generator that uses VIASPACE’s proprietary Giant King(TM) Grass as the source of continuously renewable green energy fuel.
The local “St. Croix Source” publication reported the following:
“A plan to grow 1,500 acres of hybrid Giant King Grass on St. Croix and convert it to bio-fuel for generating electricity took a step forward Tuesday night when the Public Services Commission approved Tibbar Energy USVI’s application for facility design.
By a vote of 4-0 with two absent, the PSC approved the application at its monthly meeting on St. Thomas with St. Croix commissioners Sirri Hamad and Joseph San Martin joining newly elected Commission Chairman M. Thomas Jackson and Vice-Chairwoman Elsie V. Thomas-Turton via teleconference to form a quorum.
Tibbar Energy owner Tanya Coleman and legal counsel Kevin A. Rames presented an overview of the company and adding that Giant King Grass is a fast-growing, high yield grass that is neither genetically modified nor invasive.
The Tibbar representatives told the commission the grass does not compete with other crops, is similar to sugar cane and uses a high-nutrient fertilizer water which will not deplete the soil. Farmers will be provided with free fertilizer.
Tibbar plans to create 40 new jobs in the project, they said, and hopes to harvest 500 to 600 tons a day, running the grass through an anaerobic generator which can produce up to seven kilowatts per hour. Tibbar is pursuing a contractual rate with the Water and Power Authority, Coleman said, adding that Tibbar ‘can begin to provide power by Jan. 1, 2014.’ ”
Dr. Kevin Schewe, VIASPACE’s Chairman, said, “We are certainly pleased to report that our partnership with Tibbar Energy to fuel a clean-energy 6MW anaerobic power plant with Giant King Grass on St. Croix is progressing on schedule. Our business model is to collect regular, predictable license fees as Giant King Grass is harvested by our customers over the life of their projects, and in this case, over a 20 year time frame.”
“In this 1,500 acre project using high-yielding Giant King Grass, we hope to harvest 500-600 tons of Giant King Grass per day and the harvesting is scheduled to begin in St. Croix in 2013,” he continued. “We are actively engaged in significantly larger acreage projects and in projects that we expect to serve as co-developer of the power plant where, in addition to our license fees, we could also generate recurring revenue from the sale of local electricity. We are genuinely excited about the pace and extent of our corporate progress as we head into 2013.”
For more information on VIASPACE and its Giant King Grass, visit www.VIASPACE.com
In October 2012, SoundView Research issued an investment analysis report on Viscount Systems and The IT Bridge To Physical Security. The report, summarized below, discusses major anticipated technology driven changes underway in the access control industry, and how Viscount Systems offers a unique public investment vehicles in this area, with the potential to generate multiple years of rapidly expanding revenue growth and high margins.
Viscount has launched a suite of new IP-based products that are changing the game in the physical security business, particularly building access control and management. The existing expensive and proprietary “stove-piped” industry is flipping over to modern technology. These systems are being merged with IT-based security tools and methods that leverage existing databases. An IP approach, based on standard IT infrastructure, can be expected to dominate the future of the industry, and Viscount is the only public investment vehicle of its size in this particular space, offering significant returns from current levels.
Considerations driving growth in the industry and Viscount Systems:
• A combination of acute need to comply with regulations plus intense pressure on costs is forcing enterprises to upgrade their existing access control approach and embrace open, modern technologies to lower costs and improve effectiveness.
• Organizations have invested billions in IT-based identity management and logical access security. It’s dawning on everyone that physical access control needs to be managed in the same way as an extension of these systems to eliminate the duplication of cost and effort.
• Viscount Systems has developed their “Freedom” product line into a unique and effective software solution that allows enterprises to manage identity and access management in one place and eliminate the need for expensive proprietary infrastructure.
• Viscount has substantially upgraded their company capability over the last 18 months – expanding their board of directors and advisors, opening their first field office in Washington D.C., and putting the required sales and marketing team in place.
• In the next few quarters Viscount will continue to add new revenues from the Freedom line to their existing core of business in advanced intercom systems. This will enable the company to demonstrate accelerating revenue growth and expanding operating margins.
For additional information, visit www.Viscount.com
Stellar has rapidly secured access to a key area of the burgeoning biomedical space through the development and patenting of a renewable method for extraction of KLH, or Keyhole Limpet Hemocyanin (complex oxygen-carrying metalloprotein), a vitally important and highly potent protein. KLH is derived only from the giant keyhole limpet, a kind of sea snail that lives only in the coastal waters off California. Stellar KLH™ Protein is a lucrative product with enormous potential and noteworthy market dynamics.
Stellar has the sole, crucial patent for extraction of this renewable resource and recently (Dec 4) moved to further reinforce their strong IP foundation by filing a patent application on the suKLH technology platform that included composition of matter and usages in a wide range of therapies, as well as manufacturing processes used to farm these limpets in aquaculture. Stellar really has mastered an environmentally sound, non-lethal derivation of pharmaceutical grade (GMP-grade) KLH from the little guys. It is a truly inspiring feat of modern science that blends nature with high-tech. The company is in a leadership position here with the top high molecular weight (hmwKLH) and subunit KLH (suKLH) formulations, with the suKLH formulation’s show-stopping immunogenic potency giving the company a serious edge.
Such high-quality, maximum potency vectors as those in the company’s KLH formulations allow developers to forego incorporation of otherwise dangerous adjuvants (with harmful side-effects) in order to beef up overall immunogenicity in vaccine research. Stellar is positioned to push huge shareholder return numbers due to KLH being critical to over a hundred current clinical trials in bonanza sectors like Alzheimer’s, rheumatoid arthritis, autoimmune disorders, and oncology where, collectively, the net sum quality of life result for millions of people is unquantifiable. The kind of end market territory in therapeutic vaccines and immune testing we are talking about here is incredible, and there is considerable space to develop in KLH-based assays as well, with the company’s Anti-KLH ELISA Test Kits (launched in early April), already showing solid traction in drug screening. It’s a prime example of how this technology can deliver an extremely robust test framework for judging a drug candidate’s capacity for immune system regulation.
This key immunostimulus function of KLH has made it a de facto standard as an antigen among researchers looking to push the envelope of clinical development while retaining high tolerability/safety. Major advances in immune diagnostic testing, like T-cell-dependent antibody response (TDAR, the standard immune competency benchmark for regulators and drug developers), are making KLH look more and more like a sure-fire solution for providing a clinical, trial-ready, standalone injectable for Big Pharma developers.
There are only two other manufacturers in the world for this stuff and it is virtually impossible to synthesize due to the size and complexity of the molecule. The first of those manufacturers, Sigma Aldrich, is dependent on Stellar KLH intermediate as their sole supplier. The second, a German neutricuetical firm named Biosyn (runs a CA-based subsidiary), only produces a specialized suKLH formulation (admittedly failing to produce a potent antibody response and requiring an adjuvant) developed for their own bladder cancer technology, thus any kind of real competition is virtually nil. Stellar has all the ground work laid for capturing the growing range of pharmaceutical KLH applications, and they are ready to go with land-based, scalable aquaculture farming and manufacturing, as well as the IP muscle to back this play.
The value of the company’s KLH formulations from a clinical immune-toxicity testing standpoint are particularly good, and with over a decade of research as well as $16M invested in the technology (half from the company and half from the National Institutes of Health and National Science Foundation), SBOTF today stands behind an extensive trade secret/patents pending IP portfolio that covers the U.S., Canada, France, and Germany. With the only real challenger being the German firm Biosyn and an increasingly stringent stance from FDA and EU regulators on biologicals/viral safety, the long track record for safety of the molecule combines with the company’s established reputation for superior formulation to generate a strong headwind for the Stellar Biotech ship.
The company is basically its own supplier of limpets as well, with the animal population thoroughly cultivated by SBOTF personnel at their land-based facility in Port Hueneme (under license from the US Navy and fully permitted by all relevant regulatory bodies) and any additional requirements satisfied by company divers or business relationships. Stellar can even help pharmaceutical and research clients with custom solutions via their Stellar Business Development unit, providing everything from custom assays and formulations for a specific project, to regulatory dossier support and the development of protocols or reference standards. Full access to the company’s 30-plus years of KLH-related biochemistry and technical expertise is offered as SBOTF actively seeks partnerships that can help exploit the maximum vaccine/immunodiagnostics development potential of the technology pipeline.
Current production capacity roughly exceeds all other commercial capacity and is around upwards of 800g GMP suKLH annually (1.5 Kg of starter material), with a 233% increase in annual output capacity (5Kg) on-track for the next four years, and scalability up to 20 to 100 Kg over the next seven to eight years within striking distance if demand continues to be high. Stellar signed mutual NDAs with seven of the fifteen largest biopharma developers this year and is set to pop as the company continues to draw increased attention from Big Pharma/Biotech concerns.
To learn more about Stellar Biotechnologies, visit www.StellarBiotechnologies.com
Today's Top 3
The QualityStocks Public Company Sponsor News